

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
8 August 2002 (08.08.2002)

PCT

(10) International Publication Number
WO 02/061087 A2

(51) International Patent Classification: C12N 15/12,
C07K 14/705, 16/28, G01N 33/53

[US/US]; 411 West Prospect Street, Seattle, WA 98119 (US).

(21) International Application Number: PCT/US01/50107

(74) Agents: KING, Joshua et al.; Graybeal Jackson Haley LLP, Suite 350, 155 - 108th Avenue Northeast, Bellevue, WA 98004-5901 (US).

(22) International Filing Date:

19 December 2001 (19.12.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

60/257,144 19 December 2000 (19.12.2000) US

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(63) Related by continuation (CON) or continuation-in-part (CIP) to earlier application:

US 60/257,144 (CIP)
Filed on 19 December 2000 (19.12.2000)

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (*for all designated States except US*): LIFESPAN BIOSCIENCES, INC. [US/US]; 2401 Fourth Avenue, Suite 900, Seattle, WA 98121 (US).

Published:

— without international search report and to be republished upon receipt of that report

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): BURMER, Glenna, C. [US/US]; 7516-55th Place Northeast, Seattle, WA 98115 (US). ROUSH, Christine, L. [US/US]; 5301 Eight Avenue Northeast, Seattle, WA 98105 (US). BROWN, Joseph, P.

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 02/061087 A2

(54) Title: ANTIGENIC PEPTIDES, SUCH AS FOR G PROTEIN-COUPLED RECEPTORS (GPCRS), ANTIBODIES THERETO, AND SYSTEMS FOR IDENTIFYING SUCH ANTIGENIC PEPTIDES

(57) Abstract: The present invention provides antigenic peptides for GPCRs and antibodies relating thereto, and related systems, methods, compositions, and the like, such as diagnostics and medicaments. Where antibodies against a given GPCR are not known, the present invention provides such antibodies, and preferred antigenic sequences for producing such antibodies. Where antibodies against a given GPCR are known, the present invention provides preferred antigenic peptides for producing antibodies that exhibit improved specificity, affinity or capacity to perform antibody-related actions relative to the known antibodies.

binding partners can be cloned, expressed, isolated, purified, and otherwise obtained or manipulated according to routine methods known in the art in view of the present application.

[129] The present invention further relates to antigenic peptides having an amino acid sequence from a particular GPCR, including analogs, mimetics, fragments, derivatives, and the like of such antigenic peptides. See SEQ ID NOS. 1-2292, Figures 1-3. The antigenic peptides may be recombinant, natural or synthetic. The antigenic peptides include (i) antigenic peptides in which one or more of the amino acid residues are substituted with a conserved or non-conserved amino acid residue (preferably a conserved amino acid residue) and such substituted amino acid residue may or may not be one encoded by the genetic code, (ii) antigenic peptides in which one or more of the amino acid residues includes a substituent group, (iii) antigenic peptides in which the mature polypeptide is complexed (*e.g.*, fused or otherwise bonded) with another compound, such as a compound to increase the half-life of the polypeptide (for example, polyethylene glycol), and (iv) antigenic peptides in which additional amino acids are fused to the antigenic peptide. Preparing and using such analogs, etc., are within the scope of those skilled in the art in view of the present application. The antigenic peptides additionally include antigenic peptides that have at least about 90% identity to the given antigenic peptide, and preferably at least about 95% identity to the antigenic peptide. The antigenic peptides additionally include antigenic peptides that contain at least five, six, seven or more consecutive amino acids that are identical to the given antigenic peptide, as well as antigenic peptides that contain at least six, seven, eight or more consecutive amino acids that are identical to the given antigenic except for one or two conservative changes within this such stretch of amino acids. The antigenic peptides of the present invention can be produced by peptide synthesis.

[130] EXPRESSION PROFILES BASED ON PROTEINS:

[131] An expression profile of a particular GPCR in one or more tissues can be made using antibodies or other binding partners produced using the antigenic peptides herein, then using traditional approaches such as Western blotting, immunohistochemistry analysis, protein array, ligand-binding studies, radioimmunoassay (RIA), and high performance liquid chromatography (HPLC), and immunohistochemistry analysis. H&E staining and other analyses can be used in combination with such immunologically-based analyses.

[132] SCREENING FOR ACTIVITY: